Biogen (BIIB) EBIT (2009 - 2026)

Biogen (BIIB) has reported EBIT for 18 consecutive years, with -$283.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT rose 10.94% year-over-year to -$283.3 million; the TTM figure through Mar 2026 stood at -$812.9 million (down 26.01% YoY), while the FY2025 annual figure was -$847.7 million, down 109.62% from the prior year.
• EBIT came in at -$283.3 million for Q1 2026 at Biogen, up from -$551.5 million in the prior quarter.
• The five-year high for EBIT was $901.6 million in Q3 2022, with the low at -$800.8 million in Q3 2023.
• Average EBIT over 5 years is $24.7 million, with a median of -$77.4 million recorded in 2024.
• The largest YoY upside for EBIT was 76.56% in 2024 against a maximum downside of 328.84% in 2024.
• Year by year, EBIT stood at $439.8 million in 2022, then plunged by 70.99% to $127.6 million in 2023, then sank by 328.84% to -$292.0 million in 2024, then plunged by 88.87% to -$551.5 million in 2025, then surged by 48.63% to -$283.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$283.3 million, -$551.5 million, and -$117.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.